Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapeutic effects of direct renin inhibitor aliskiren added to AT1 receptor blocker in hypertensive patients with chronic kidney disease.

Next Previous
Trial Profile

Therapeutic effects of direct renin inhibitor aliskiren added to AT1 receptor blocker in hypertensive patients with chronic kidney disease.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary) ; Benazepril (Primary)
  • Indications Hypertension
  • Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 19 Sep 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
  • 04 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
  • 29 Apr 2012 Interim results presented at the 22nd European Meeting on Hypertension.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top